Meetings & Presentations2026-09-28

Prulacabtagene leucel (prula-cel, formerly ADI-001)

Adicet Bio Inc.ACET
Indication
Systemic lupus erythematosus (SLE)
Stage
phase2
Event
Conference Presentation
Details

September 28, 2026: Adicet Bio, Inc. (NASDAQ: ACET) said it will report clinical data from its Phase 1 study of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus, with or without lupus nephritis. The company plans to host a webcast presentation at 8:00 a.m. ET the same day to discuss the results. The announcement identifies this as an upcoming clinical data readout catalyst for prula-cel; no efficacy or safety results were disclosed in the content provided.